Navigation Links
NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/25/2009

d surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel Plus(R), and the Progentix(R) products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the risk that the Company may not be successful in integrating acquired technology or products, such as the Progentix family of products; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's revenue or profitability projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases a
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
2. NuVasive to Present at Canaccord Adams Musculoskeletal Conference
3. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
4. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
5. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
6. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
7. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
8. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
9. NuVasive Acquires First Stem Cell Bone Graft Substitute
10. NuVasive Reports First Quarter 2008 Financial Results
11. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... about the brain affect the course of a criminal trial, ... a sentence? This was the topic of ... for Neuroscience,s "Neuroscience 2011." Titled "The Brain on Trial: Neuroscience ... neuroscience are both challenging and assisting the judicial system. To ...
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... SAN DIEGO - A new, targeted approach to treating ... Phase I/II clinical trial for patients with relapsed or ... of the American Society of Hematology. "PCI-32765, one ... cell receptor inhibitors, has shown impressive potential in this ...
... FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is easy ... your health during the flu season, but too few Americans ... off concerns about the flu, yet every year it strikes ... to the hospital and killing thousands," Dr. Thomas Slama, president ...
... Terrorist attacks with chemical weapons are a real possibility, ... access journal, Journal of Pharmacy Practice , published by ... how to treat those who have been exposed, pharmacists are ... potential chemical weapons attack. Chemical weapons act on their ...
Cached Medicine News:Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 2Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 3Health News:B cell receptor inhibitor causes chronic lymphocytic leukemia remission 2Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Pharmacists crucial in plan for terrorist chemical weapons 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... (Nasdaq: ENMD ), a clinical-stage pharmaceutical company ... that Selected Value Therapeutics I, LLC (SVT) has exercised ... and commercialize EntreMed,s Phase 2 oncology drug candidate, ENMD-2076, ... development and commercialization rights to ENMD-2076 in the rest ...
... 2011 The ALS Therapy Development Institute (ALS TDI) ... (D-MA) with its first ever "Lou Gehrig Award" during ... event this November 3rd.  The award recognizes the Congressman ... additional funding for research leading to an effective treatment ...
Cached Medicine Technology:Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 2Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 3Selected Value Therapeutics Exercises Right to Develop and Commercialize ENMD-2076 in China 4U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS TDI During Gala Event this November 2
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: